description
Powered by Eupheria Biotech
Quality Level
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
AAAAGGCACTGCTAAGACATTCAAGCAAATAGCTATTACACACTACTGCAGATTTTACAGGTTTCTAATTCTAACATATGTTTGAAAAATCCGTGAGTATTCCAAAATATATTTAATAATGGAATATCTGCATTAATATACCATCCATGTGTTTTTACCATTTGCCTTAATATTGAATATACTGTTTACCTCACACTAAAAAGAAAACCAGAAGCCTTATTTGTGATTTTGGGAGTGGAAGCTTCCATTTTTGTGTCAAAAATGAATCCTGATTCTTATGGAAATCTCTGTTATTAAGATATTTCAAGATGAGACAACACTGAAGATCAAATTGTGTTTAGTATCACTATCTTCTCTCCTCGTTTCTCTCTTACTCCTCATCCTCCCAGAATCTACCAGT
Ensembl | human accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Gene Information
human ... SUCLG2(8801)
General description
MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Shian-Ren Lin et al.
Oncogene, 39(44), 6757-6775 (2020-09-24)
Neuroendocrine (NE) differentiation is a well-recognized phenotypic change of prostate cancer after androgen deprivation therapy (ADT), and it ultimately develops into an aggressive subset of this disease. However, the contribution of signaling pathways that lead to metabolic disorders and NE
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| EHU140901-50UG | 04061828414031 |
| EHU140901-20UG | 04061828638888 |